{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974910",
  "id": "02974910",
  "pages": 8,
  "price_sensitive": true,
  "date": "20250731",
  "time": "0845",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mbzj1zcktpd2.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Clinical Trial Updates (Material Operational Highlights)**  \n- **ACCENT Trial Results**:  \n  - 17 confirmed partial responses (31% response rate) for narmafotinib + chemotherapy vs. 23% for chemo alone.  \n  - Two complete responses, including one pathological complete response in metastatic pancreatic cancer (exceptionally rare).  \n- **New Trial Progress**: Ethics approvals secured in US/Australia for FOLFIRINOX combo trial; dosing stage imminent.  \n\n#### **Capital Raising (Material Financial Event)**  \n- **Structure**: Placement ($25M) + Share Purchase Plan ($2.5M).  \n- **Use of Proceeds**: Funds clinical trials; extends cash runway to 2027.  \n\n#### **Financial Position (Appendix 4C)**  \n- **Closing Cash (30 June 2025)**: $7.0M (down from $10.9M in March 2025).  \n- **Quarterly Cash Burn**: $3.8M (R&D: $3.0M; corporate: $0.9M).  \n- **Expected Inflows**: $3.8M R&D tax refund in September 2025.  \n\n#### **Forward Outlook**  \n- Focus on ACCENT data updates, FOLFIRINOX trial initiation, and FDA engagement.  \n\n**Omitted**: Non-material details (e.g., CMO appointment, conference presentation).",
  "usage": {
    "prompt_tokens": 4666,
    "completion_tokens": 298,
    "total_tokens": 4964,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T23:00:23.760329"
}